Condition: Non-metastatic Soft-tissue Sarcoma · Resectable · Sponsor: Institut Bergonié
The primary objective of this trial is to investigate whether the addition of 3 additional neo-adjuvant cycles of chemotherapy (doxorubicin based chemotherapy) to standard management according to the ISG-STS 10-01 study (3 cycles of neoadjuvant doxorubicin based chemotherapy + surgery +/- radiotherapy) improves the outcome of high-risk CINSARC patients with resectable soft-tissue sarcoma (STS). Primary endpoint is metastatic progression-free survival (M-PFS, after 3 years of follow-up).
This description comes directly from the study's public registry record.
Antoine ITALIANO, MD, PhD · +33 5.56.33.33.33 · a.italiano@bordeaux.unicancer.fr
Simone MATHOULIN-PELISSIER, MD, PhD · m.mathoulin@bordeaux.unicancer.fr
Always discuss trial participation with your own doctor first.
| Institut Bergonie | Bordeaux, France | Recruiting |
| Centre Georges François Leclerc | Dijon, France | Recruiting |
| CHU Dupuytren | Limoges, France | Recruiting |
| Centre Léon Bérard | Lyon, France | Recruiting |
| Institut Paoli Calmettes | Marseille, France | Recruiting |
| Insitut du Cancer | Montpellier, France | Recruiting |
| Institut de Cancérologie de l'Ouest - Site René Gauducheau | Saint-Herblain, France | Recruiting |
| CHRU Strasbourg | Strasbourg, France | Recruiting |
| Institut Claudius Regaud | Toulouse, France | Recruiting |
| Institut Gustave Roussy | Villejuif, France | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03805022